Floatz logo

bp102

Malignant Solid Tumors

Shanghai Hengrui Pharmaceutical Co., Ltd.Phase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
81/ 100

Competitive context

29 Active assets in the Malignant Solid Tumors cohort.

Asset / SponsorPhaseRating
Peg-Rhg-Csf
CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.
Phase 4B
Medroxyprogesterone acetate
The First Affiliated Hospital of Xinxiang Medical College
Phase 3B
Zofran
The First Affiliated Hospital of Xinxiang Medical College
Phase 3B
Phosphonic acid, P-[3-[[(2R,3R)-2-[(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethoxy]-3-(4-fluorophenyl)-4-morpholinyl]methyl]-2,5-dihydro-5-oxo-1H-1,2,4-triazol-1-yl]-
The First Affiliated Hospital of Xinxiang Medical College
Phase 3B
DEXAMETHASONE
The First Affiliated Hospital of Xinxiang Medical College
Phase 3B

View all 38 →

Same molecule, other indications

bp102 is also rated in:

Advanced or Metastatic Non-squamous Non-small Cell Lung CancerDormant
BB
Indicative ·
64 / 100
View asset →
cancerDormant
B
Indicative ·
60 / 100
View asset →
triple-negative breast carcinomaDormant
CCC
Indicative ·
53 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →